Gastrointestinal Tumors最新文献

{"title":"Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 72-4 in Gastric Cancer: Is the Old Band Still Playing?","authors":"Andrey Iskrenov Kotzev,&nbsp;Peter Vassilev Draganov","doi":"10.1159/000488240","DOIUrl":"https://doi.org/10.1159/000488240","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer (GC) is characterized by aggressive behavior and a high mortality rate. The diagnosis of GC is challenging because the GC is often diagnosed in an advanced stage. The use of tumor markers is a putative way to improve the detection and treatment in patients with GC.</p><p><strong>Summary: </strong>In this article, we review the significance of serum carbohydrate antigen (CA) 19-9, carcinoembryonic antigen (CEA), and CA 72-4 in GC. The results from different studies regarding the diagnostic and prognostic role of CA 19-9, CEA, and CA 72-4 in GC are encouraging, but inadequate sensitivity and specificity obstruct their use as standardized and unconditionally reliable markers in GC. New prospective clinical trials are mandatory for clarifying their value in GC.</p><p><strong>Key message: </strong>CA 19-9, CEA, and CA 72-4 should not be used for screening and early diagnosis in GC, whereas they are beneficial in the detection of late GC. CA 19-9, CEA, and CA 72-4 could be used as prognostic and monitoring tools in GC, and their combined measurement in shorter periods of time is the best method to increase sensitivity and specificity.</p><p><strong>Practical implications: </strong>Serum CA 19-9, CEA, and CA 72-4 are useful diagnostic and prognostic tumor markers in GC.</p>","PeriodicalId":45017,"journal":{"name":"Gastrointestinal Tumors","volume":"5 1-2","pages":"1-13"},"PeriodicalIF":1.6,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000488240","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36805666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraplatelet Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor: New Biomarkers in Carcinoembryonic Antigen-Negative Colorectal Cancer?","authors":"Charbel Chater,&nbsp;Anne Bauters,&nbsp;Claire Beugnet,&nbsp;Lena M'Ba,&nbsp;Moshe Rogosnitzky,&nbsp;Philippe Zerbib","doi":"10.1159/000486894","DOIUrl":"https://doi.org/10.1159/000486894","url":null,"abstract":"<p><strong>Background/aim: </strong>Colorectal cancer (CRC) is associated with high incidence and mortality rates. Carcinoembryonic antigen (CEA), a prognostic biomarker for recurrent CRC following curative resection, suffers from low sensitivity, especially in early-stage screening. Intraplatelet angiogenesis regulators (IPAR), such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), have been identified as important regulators of tumor growth in CRC. The aim of this study was to confirm the higher preoperative level of IPAR (VEGF and PDGF) in CRC patients compared to controls and to measure IPAR in CEA-negative CRC patients.</p><p><strong>Methods: </strong>The data and blood of 30 CRC patients and 30 presumably healthy controls were prospectively analyzed and compared.</p><p><strong>Results: </strong>We confirmed elevated preoperative intraplatelet VEGF and PDGF levels in CRC patients compared to controls. Importantly, IPAR were significantly elevated even in CEA-negative CRC patients.</p><p><strong>Conclusion: </strong>Elevated preoperative intraplatelet VEGF and PDGF levels in CRC patients suggest new possibilities for postoperative monitoring in CRC patients, especially when CEA is negative.</p>","PeriodicalId":45017,"journal":{"name":"Gastrointestinal Tumors","volume":"5 1-2","pages":"32-37"},"PeriodicalIF":1.6,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000486894","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36805668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Network Meta-Analysis of Adjuvant Chemotherapy following Resection of Colorectal Liver Metastases.","authors":"Paschalis Gavriilidis,&nbsp;Aurelio Tobias,&nbsp;Robert P Sutcliffe,&nbsp;Daniel Azoulay,&nbsp;Keith J Roberts","doi":"10.1159/000490763","DOIUrl":"https://doi.org/10.1159/000490763","url":null,"abstract":"<p><strong>Objective: </strong>Six principal adjuvant chemotherapy treatments (ACTs) are currently available for patients with resected colorectal liver metastases. This meta-analysis was designed to determine the optimal ACT, as evaluated by 2-year disease-free survival (DFS) and 5-year overall survival (OS) rates as well as by hepatic recurrences and adverse events (AEs).</p><p><strong>Methods: </strong>A systematic literature search of the PubMed, EMBASE, Medline, Cochrane Library, and Google Scholar databases was performed. The probability of the optimal therapeutic scheme and the mean ranking were estimated for each treatment using network meta-analysis.</p><p><strong>Results: </strong>Systemic chemotherapy (SCT) had the best 2-year DFS rate (hazard ratio [HR] = 0.78, 95% confidence interval [CI] = 0.48-1.27, 95% prediction interval [PI] = 0.17-3.56, surface under the cumulative ranking area [SUCRA] = 73) and the lowest AE rate (estimated SUCRA = 65 and predicted SUCRA = 62). Hepatic arterial infusion (HAI) plus SCT had the best 5-year OS rate (HR = 0.81, 95% CI = 0.64-1.01, 95% PI = 0.50-1.29) and the lowest hepatic recurrence rate (odds ratio = 2.87, 95% CI = 1.56-5.30, 95% PI = 0.61-13.62).</p><p><strong>Conclusion: </strong>Both SCT and HAI plus SCT showed superior efficacy and safety. Clinical trials in homogeneous populations with strict selection criteria are needed to compare these two ACTs.</p>","PeriodicalId":45017,"journal":{"name":"Gastrointestinal Tumors","volume":"5 1-2","pages":"21-31"},"PeriodicalIF":1.6,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000490763","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36805667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression.","authors":"Leonidas Apostolidis,&nbsp;Jan Pfeiffenberger,&nbsp;Daniel Gotthardt,&nbsp;Boris Radeleff,&nbsp;Arianeb Mehrabi,&nbsp;Peter Schemmer,&nbsp;Dirk Jäger,&nbsp;Peter Schirmacher,&nbsp;Wolfgang Stremmel,&nbsp;Henning Schulze-Bergkamen,&nbsp;Christoph Springfeld,&nbsp;Karl Heinz Weiss","doi":"10.1159/000487635","DOIUrl":"https://doi.org/10.1159/000487635","url":null,"abstract":"<p><strong>Background/aim: </strong>Sorafenib leads to improved survival in advanced hepatocellular carcinoma (HCC) patients. Continuation of sorafenib beyond progression has been a possible treatment strategy when further approved therapeutic agents are lacking.</p><p><strong>Methods: </strong>We performed a retrospective analysis of all HCC patients at our institution with documented disease progression under treatment with sorafenib. Overall survival (OS) from start of sorafenib treatment was compared between patients who received sorafenib for > 3 weeks beyond progression (group 1) and those who discontinued sorafenib ≤3 weeks after progression (group 2). Group 1 was further subdivided into those patients who received sorafenib for > 3 months (group 1a) and those who received it for ≤3 months (group 1b).</p><p><strong>Results: </strong>A total of 71 patients were analyzed. Median OS for all patients was 15.4 months. OS in group 1 (15.6 months) and 2 (13.0 months) was similar (<i>p</i> = 0.90). Patients in group 1a showed significantly prolonged median OS (19.7 months) compared to that of patients in group 1b (13.6 months, <i>p</i> = 0.004), and they showed a trend towards prolonged OS compared to group 2 (<i>p</i> = 0.126). For patients with a poor prognosis according to their Child-Pugh stage, performance status, alpha-fetoprotein, and response to prior sorafenib treatment, OS was significantly prolonged in group 1 versus group 2 (12.1 vs. 6.4 months, <i>p</i> = 0.019).</p><p><strong>Conclusion: </strong>In HCC patients, continuing sorafenib beyond progression for > 3 months is associated with improved survival compared to discontinuing sorafenib within 3 months. Furthermore, patients with a poor prognosis who continue sorafenib beyond progression in general show significantly prolonged survival.</p>","PeriodicalId":45017,"journal":{"name":"Gastrointestinal Tumors","volume":"5 1-2","pages":"38-46"},"PeriodicalIF":1.6,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000487635","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36805669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond the Beyond: A Case of an Extraordinary Response to Multiple Lines of Therapy in a de novo Metastatic HER2-Negative Gastric Cancer Patient.","authors":"Cinzia Baldessari,&nbsp;Fabio Gelsomino,&nbsp;Andrea Spallanzani,&nbsp;Giuseppe Pugliese,&nbsp;Luca Reggiani Bonetti,&nbsp;Stefania Bettelli,&nbsp;Stefano Cascinu","doi":"10.1159/000488983","DOIUrl":"https://doi.org/10.1159/000488983","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer is the fourth cause of cancer-related death in Europe and the prognosis of these patients remains dismal. It has been demonstrated that chemotherapy improved survival compared with best supportive care and recently, subsequent lines of therapy, also with new drugs, obtained positive results.</p><p><strong>Summary: </strong>We present the case of a patient diagnosed with a de novo metastatic gastric cancer who experienced an extraordinary long response to multiple lines of chemotherapy (FOLFOX6, paclitaxel plus ramucirumab, FOLFIRI, rechallenge with FOLFOX6).</p><p><strong>Key message: </strong>Gastric cancer therapy should be considered as the result of a strategy based on the patient's condition, and tolerance and response to various therapies. The emerging evidence of the role of subsequent lines of therapy, along with the recognition of the pivotal role of nutritional support and the availability of new drugs, should help clinicians in the management of patients with gastric cancer.</p><p><strong>Practical implications: </strong>We propose a practical therapeutic algorithm in order to help clinicians who deal with patients with gastric cancer.</p>","PeriodicalId":45017,"journal":{"name":"Gastrointestinal Tumors","volume":"5 1-2","pages":"14-20"},"PeriodicalIF":1.6,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000488983","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36805665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"No Evidence for an Association between JC Polyomavirus Infection and Gastroduodenal Diseases.","authors":"Azadeh Yazdani Cherati,&nbsp;Yousef Yahyapour,&nbsp;Mohammad Ranaee,&nbsp;Mehdi Rajabnia,&nbsp;Javad Shokri Shirvani,&nbsp;Mahmoud Hajiahmadi,&nbsp;Farzin Sadeghi","doi":"10.1159/000489928","DOIUrl":"https://doi.org/10.1159/000489928","url":null,"abstract":"<p><strong>Background: </strong><i>Helicobacter pylori</i> (HP) infection is one of the hypothesized infectious etiologies of gastric cancer (GC) and other gastroduodenal diseases. It was suggested that other infectious agents, including oncogenic viruses, may increase the risk of gastroduodenal diseases. A number of reports regarding JC polyomavirus (JCPyV) have shown that JCPyV could be implicated in colorectal cancer and gastrointestinal carcinogenesis.</p><p><strong>Objective: </strong>The current investigation aimed to investigate whether JCPyV could have any association with the pathogenesis of gastroduodenal diseases either alone or together with HP.</p><p><strong>Methods: </strong>A total of 237 fresh or formalin-fixed and paraffin-embedded gastroduodenal samples were examined by quantitative real-time polymerase chain reaction targeting the JCPyV large tumor antigen (LTag) oncogene, and viral load was determined as viral copy number/cell.</p><p><strong>Results: </strong>In total, 2 out of 237 samples (0.8%) were positive for JCPyV LTag DNA. One positive sample derived from diffuse-type gastric adenocarcinoma (6.8 × 10^-3 copies/cell) and other JCPyV-positive sample obtained from a patient with gastritis (2.5 × 10^-3 copies/cell) were recorded. Both JCPyV-positive samples were negative for HP infection.</p><p><strong>Conclusion: </strong>This study suggests no association between JCPyV infection and GC or other gastroduodenal diseases. The very low frequency of JCPyV LTag sequences in GC is an important aspect that weakens the hypothesis of the pathogenic role of JCPyV in gastric tumor induction.</p>","PeriodicalId":45017,"journal":{"name":"Gastrointestinal Tumors","volume":"5 1-2","pages":"47-53"},"PeriodicalIF":1.6,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000489928","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36805670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Front & Back Matter","authors":"J. Szepietowski, E. Weisshaar, V. Blanchette, L. Brandão, V. Breakey, S. Revel-Vilk, Q. Nguyen, E. Rodrigues, M. Farah, W. Mieler, D. Do, O. Michielin, G. Coukos, Jing-yuan Fang, P. Malfertheiner, M. Büchler","doi":"10.1159/000493441","DOIUrl":"https://doi.org/10.1159/000493441","url":null,"abstract":"submission deadline: 6 April 2018 Early registration deadline: 25 June 2018 www.ilca2018.org THE INTERNATIONAL LIVER CANCER ASSOCIATION ANNOUNCES ITS 12 TH ANNUAL CONFERENCE","PeriodicalId":45017,"journal":{"name":"Gastrointestinal Tumors","volume":"5 1","pages":""},"PeriodicalIF":1.6,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42976199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Finally, a Minimally Invasive Option for Intrahepatic Inferior Vena Cava Invasion by Hepatocellular Carcinoma.","authors":"Erik Soule,&nbsp;Jerry Matteo","doi":"10.1159/000491694","DOIUrl":"https://doi.org/10.1159/000491694","url":null,"abstract":"<p><strong>Background: </strong>Major vessel invasion is a late manifestation of hepatocellular carcinoma, which may directly result in mortality if left untreated. Surgical resection may be an option for select patients; however, surgery may be contraindicated. Contraindications include multifocal disease, poor liver reserve, inability to tolerate surgery, and patient preference. Cryoablation is a minimally invasive therapy utilized for treating hepatic neoplasms by subjecting them to extreme cold temperatures. The \"thermal sink\" effect describes cryoablation near flowing blood such as that found in high volumes within major vascular structures. Thermodynamics dictates that proximity to the flowing intravascular compartment will decrease ice formation, and therefore, tumor destruction.</p><p><strong>Methods: </strong>This report describes a novel palliative technique to induce temporary cessation of the blood flow in the intrahepatic inferior vena cava (IVC), thus enabling the operator to perform cryoablation targeting invasive cancer within.</p><p><strong>Results: </strong>Adequate ablation using this technique allowed a patient with IVC invasion 9 months of survival.</p><p><strong>Conclusion: </strong>Quality of life during this time was maximized, as recovery time from this procedure is minimal.</p>","PeriodicalId":45017,"journal":{"name":"Gastrointestinal Tumors","volume":"5 1-2","pages":"54-61"},"PeriodicalIF":1.6,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000491694","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36804639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contents Volume 4, 2017","authors":"P. Malfertheiner, Jing-yuan Fang, P. Malfertheiner, M. Büchler, Y. Kodera, Yingbin Liu, K. Mönkemüller, G. Nakayama, G. Rogler, M. Scharl, Jianqiu Sheng, Masao Tanaka, J. Lanschot, Ming-Rong Wang, B. Wiedenmann, Kaichun Wu, Jie Xu, P. Zhou","doi":"10.1159/000487415","DOIUrl":"https://doi.org/10.1159/000487415","url":null,"abstract":"","PeriodicalId":45017,"journal":{"name":"Gastrointestinal Tumors","volume":"4 1","pages":"I - II"},"PeriodicalIF":1.6,"publicationDate":"2018-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000487415","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44340467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Three-Dimensional Surgical Simulation on Pancreatic Surgery.","authors":"Ryoichi Miyamoto,&nbsp;Yukio Oshiro,&nbsp;Ken Nakayama,&nbsp;Nobuhiro Ohkohchi","doi":"10.1159/000484894","DOIUrl":"https://doi.org/10.1159/000484894","url":null,"abstract":"<p><strong>Background/aims: </strong>Anatomical variations are frequently encountered during hepato-biliary-pancreatic surgeries, requiring surgeons to have a precise understanding of the surgical anatomy in order to perform a safe surgery. We evaluated the impact of novel three-dimensional (3D) surgical simulation on pancreatic surgeries to enhance surgical residents' understanding.</p><p><strong>Methodology: </strong>Between January 2013 and May 2014, 61 preoperative 3D surgical simulations were performed. The consistency (0-10, with 10 representing 100% consistency) among the 15 surgical residents' anatomical drawings from multidetector computed tomography images and the simulated 3D images by SYNAPSE VINCENT® was assessed. We divided the surgical residents into two groups - first- to fifth-year postgraduate doctors (group A) and sixth- to tenth-year postgraduate doctors (group B) - and compared the self-assessment scores between these two groups.</p><p><strong>Results: </strong>In terms of the self-assessment scores, a statistically significant difference was observed between the two groups (<i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>In this study, 3D surgical simulation was useful for preoperative assessments prior to pancreatic surgery, especially in younger postgraduate surgeons.</p>","PeriodicalId":45017,"journal":{"name":"Gastrointestinal Tumors","volume":"4 3-4","pages":"84-89"},"PeriodicalIF":1.6,"publicationDate":"2018-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000484894","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35956785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}